Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/172527
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abdullah Al-Zaher, Ahmed | - |
dc.contributor.author | Moreno Olié, Rafael | - |
dc.contributor.author | Fajardo Calderón, Carlos Alberto | - |
dc.contributor.author | Arias Badia, Marcel | - |
dc.contributor.author | Farrera, Martí | - |
dc.contributor.author | Sostoa, Jana de | - |
dc.contributor.author | Rojas Expósito, Luis Alfonso | - |
dc.contributor.author | Alemany Bonastre, Ramon | - |
dc.date.accessioned | 2020-12-09T16:32:38Z | - |
dc.date.available | 2020-12-09T16:32:38Z | - |
dc.date.issued | 2018-01-01 | - |
dc.identifier.uri | http://hdl.handle.net/2445/172527 | - |
dc.description.abstract | To enhance adenovirus-mediated oncolysis, different approaches that tackle the selectivity, tumor penetration, and spreading potential of oncolytic adenoviruses have been reported. We have previously demonstrated that insertion of the internalizing Arginine-Glycine-Aspartic (iRGD) tumor-penetrating peptide at the C terminus of the fiber or transgenic expression of a secreted hyaluronidase can improve virus tumor targeting and spreading. Here we report a new oncolytic adenovirus ICOVIR17K-iRGD in which both modifications have been incorporated. In xenografted A549 tumors in nude mice, ICOVIR17K-iRGD shows higher efficacy than the non-iRGD counterpart. To gain insights into the role of the immune system in oncolysis, we have studied ICOVIR17K-iRGD in the tumor isograft mouse model CMT64.6, partially permissive to human adenovirus 5 replication, in immunodeficient or immunocompetent mice. Whereas no efficacy was observed in the immunodeficient setting due to insufficient viral replication, partial efficacy and a polymorphonuclear and CD8+ T cell infiltrate were observed in the immunocompetent mice. The results indicate that the elicitation of a virus-induced anti-tumoral immune response is responsible for the observed partial antitumoral effect. | - |
dc.format.extent | 9 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Cell Press | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.omto.2018.01.003 | - |
dc.relation.ispartof | Molecular Therapy-oncolytics, 2018, vol. 8, p. 62-70 | - |
dc.relation.uri | https://doi.org/10.1016/j.omto.2018.01.003 | - |
dc.rights | cc by (c) Abdullah Al-Zaher, Ahmed et al., 2018 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Adenovirus | - |
dc.subject.classification | Tumors | - |
dc.subject.classification | Adjuvants immunològics | - |
dc.subject.other | Adenoviruses | - |
dc.subject.other | Immunological adjuvants | - |
dc.subject.other | Tumors | - |
dc.title | Evidence of Anti-tumoral Efficacy in an Immune Competent Setting with an iRGD-Modified Hyaluronidase-Armed Oncolytic Adenovirus | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2020-12-02T10:00:39Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29888319 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Al-ZaherAA.pdf | 1.41 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License